The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Mar 2016 10:34

RNS Number : 0284T
Hutchison China Meditech Limited
23 March 2016
 

 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Hutchison China MediTech Limited

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Change in total voting rights of the issuer

ü

3. Full name of person(s) subject to thenotification obligation: iii

Hutchison Healthcare Holdings Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

22 March 2016

6. Date on which issuer notified:

22 March 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

64%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary

36,666,667

36,666,667

36,666,667

36,666,667

60.82

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

36,666,667

60.82%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Hutchison Healthcare Holdings Limited is a wholly owned subsidiary of Hutchison Whampoa (China) Limited, which is an indirect wholly-owned subsidiary of CK Hutchison Holdings Limited - 36,666,667 ordinary shares (60.82%)

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Edith Shih

15. Contact telephone number:

+852 2128 1232

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOURRNVAOUAR
Date   Source Headline
26th Mar 20187:00 amRNSAnnual Report & Notice of Annual General Meeting
21st Mar 20189:25 amRNSDirector's Share Dealing
20th Mar 20189:15 amRNSGrant of Share Options under Share Option Scheme
19th Mar 20187:10 amRNSDirector's Share Dealing
12th Mar 201811:22 amRNSPublication of Form 20-F
12th Mar 20187:02 amRNSFinal Results and Key Clinical Programs Update
6th Mar 20187:00 amRNSPhase Ib/II Trial of Epitinib in Glioblastoma
13th Feb 20187:01 amRNSEnrolment completed Ph III FALUCA Fruquintinib
5th Feb 20187:00 amRNSChi-Med to Announce 2017 Final Results
29th Dec 20177:00 amRNSBlock listing Interim Review
29th Dec 20177:00 amRNSTotal Voting Rights
15th Dec 20177:00 amRNSChi-Med Initiates Fruquintinib US Clinical Trials
1st Nov 20179:45 amRNSNotification of Major Holdings
1st Nov 20179:45 amRNSNOTIFICATION OF MAJOR HOLDINGS
31st Oct 20177:00 amRNSFRUTIGA, a Phase III trial of Fruquintinib
30th Oct 20173:30 pmRNSClosing of U.S. Public Offering of ADSs
27th Oct 201712:10 pmRNSChi-Med Announces Over-allotment Option
26th Oct 20177:00 amRNSChi-Med Announces Pricing Raising US$262 million
25th Oct 20177:00 amRNSChi-Med Announces Proposed Offering of ADSs
19th Oct 20179:20 amRNSNotification of Major Interest in Shares
17th Oct 20177:00 amRNSSavolitinib Shows Encouraging Clinical Activity
16th Oct 20177:00 amRNSChi-Med Reports Preliminary Phase II data
12th Oct 20177:30 amRNSAppointment of Director
29th Sep 20177:04 amRNSSavolitinib and Fruquintinib presentations at WCLC
29th Sep 20177:00 amRNSTotal Voting Rights
29th Sep 20177:00 amRNSOral Presentations at CSCO Annual Meeting
31st Aug 201710:15 amRNSDirector's Share Dealing
29th Aug 20177:00 amRNSStart of HMPL 689 Phase I Trial in China
22nd Aug 20179:00 amRNSDirector's Share Dealing
18th Aug 201710:50 amRNSDirectors' Share Dealing
15th Aug 201710:30 amRNSDirectors' Share Dealing
10th Aug 20179:35 amRNSDirector's Share Dealing
7th Aug 20179:45 amRNSDirectors' Share Dealing
31st Jul 20177:00 amRNSChi-Med Reports 2017 Interim Results
30th Jun 20177:00 amRNSTotal Voting Rights
29th Jun 20177:00 amRNSChi-Med to Announce 2017 HY Financial Results
29th Jun 20177:00 amRNSBlocklisting Six Monthly Return
29th Jun 20177:00 amRNSStart of Savolitinib Global PRCC Phase III Trial
22nd Jun 20177:00 amRNSChi-Med starts Ph I/II Trial of HMPL 453 in China
16th Jun 20179:57 amRNSDirector's Share Dealing
12th Jun 20177:00 amRNSFruquintinib NDA for Advanced CRC Filed with CFDA
6th Jun 20177:00 amRNSPhase III Fruquintinib Data presented at ASCO
18th May 20177:00 amRNSChi-Med Presents Clinical Data at ASCO 2017
28th Apr 20171:40 pmRNSTotal Voting Rights
27th Apr 20172:10 pmRNSResults of Annual General Meeting
7th Apr 20177:00 amRNSPre-clinical Data Presented at AACR
31st Mar 20177:00 amRNSTotal Voting Rights
29th Mar 20178:07 amRNSVesting of LTIP awards
28th Mar 201711:00 amRNSGrant of Share Options under Share Option Scheme
27th Mar 20177:00 amRNS2016 Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.